Israel’s BiolineRX is to conduct Phase 1 clinical trials on sickle cell disease (SCD) patients at multiple locations in the US.  It will use its motixafortide stem cell therapy (see here previously), currently used to treat multiple myeloma. SCD is … Continue reading →

This article identifies three more Israeli companies that are expected to receive FDA approval for treatments in 2023. They are Gamida Cell (Omidubicel / NiCord – bone marrow transplants); Protalix (PRX-102 – Fabry disease); and BioLineRX (BL-8040 / Motixafortide – … Continue reading →

Israel’s BioLineRx (see here previously) has reported positive results in the Phase 3 trial of its Motixafortide treatment in combination with G-CSF for multiple myeloma. The treatment demonstrated improvement from five-fold to 14-fold compared to the control. https://en.globes.co.il/en/article-biolinerx-soars-on-positive-phase-3-blood-cancer-trial-results-1001347840 https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-positive-top-line-results-genesis-phase-3

The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX (see here). BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity. https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-receives-orphan-drug-designation-motixafortide-bl-8040

In the latest Phase 2a trial of the pancreatic cancer treatment from Israel’s BioLineRx (see here) three-quarters of the patients at disease stage 4 were able to get their disease under control. The trial combined BL-8040, KEYTRUDA (Pembrolizumab) and chemotherapy. … Continue reading →

FDA designation for solid tumor treatment. (TY Atid-EDI) I reported previously (28 Jan) that the AGI-134 solid tumor treatment from Israel’s BiolineRX showed promise. The U.S. FDA has just granted Biological Product Designation for the novel immunotherapy compound. Early trials … Continue reading →

Israel’s BioLineRx has announced encouraging initial results from its Phase 2a trials of its BL-8040 treatment on patients with metastatic pancreatic cancer. After only five days of treatment the treatment substantially increased the numbers of T-cells fighting the tumors. https://www.prnewswire.com/news-releases/biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-cancer-300583808.html

When Israel’s BioLineRx bought UK’s Agalimmune, it also acquired its AGI-134 treatment for solid tumors. BioLineRX has just demonstrated successful results of AGI-134 in two pre-clinical melanoma studies. https://www.prnewswire.com/news-releases/biolinerx-reports-data-at-asco-sitc-conference-showing-complete-tumor-regression-by-agi-134-in-pre-clinical-studies-670669553.html

Israel’s BiolineRx is buying UK’s Agalimmune,for $6 million. The private UK-based company has developed an innovative, anti-cancer immunotherapy platform. treatment that not only kills the tumor cells at the site of injection, but also brings about a durable, follow-on, anti-metastatic … Continue reading →